Praxis Precision Medicines delivered the week's most striking biotech setup: a 17% rally on the back of a positive earnings reaction, yet short sellers — who hold nearly 16% of the float — have barely moved.
The most telling detail this week is what shorts did not do. Short interest edged up just 1.4% over the week to roughly 15.9% of free float, despite the stock climbing from around $308 to close at $360.76 on August 7. That's a small but real increase in bearish positioning into the strength, not the cover-and-run dynamic that typically follows a double-digit move. FINRA's most recent settlement data puts short interest at approximately 3.76 million shares with a days-to-cover ratio of 9.2 — meaning it would take shorts more than nine trading days to exit at average volume. The borrow market remains easy, with availability running at a very comfortable 525%, and cost to borrow has ticked up 30% over the week to 0.58% — still negligible in absolute terms, but directionally worth noting given it is rising alongside a rising stock. The lending market is far from stressed.
Options positioning tells a different story from the shorts. The put/call ratio has pulled back sharply from its recent highs — it had been running near 3.6 through late July, then dropped to 2.6 this week. That's still well above the 52-week low of 0.64, but the directional move is meaningful: demand for downside protection is fading as the stock rips higher. At nearly one standard deviation below its 20-day average of 3.12, the PCR shift reflects growing confidence among options traders, even as short sellers dig in.
The Street reaction to earnings was swift. RBC Capital raised its target from $449 to $462 while maintaining Outperform. Wells Fargo bumped from $323 to $362, staying at Equal-Weight. Needham moved its Buy target from $575 to $582. Goldman Sachs had initiated at Buy with a $447 target in mid-July. The direction of travel is uniformly upward, but the consensus mean target of $643 — against a current price of $360 — reveals just how wide the range of outcomes remains. Bulls point to ulixacaltamide's multi-billion dollar market potential and a largely de-risked pipeline with two assets near FDA review. Bears cite the earlier miss on vormatrigine's focal onset seizure study and the dependence on regulatory timelines that remain outside the company's control. The analyst recommendation divergence factor ranks in the 92nd percentile, indicating an unusually large gap between the most bullish and most cautious views on the Street.
On the ownership side, two moves stand out. FMR (Fidelity) added 801,000 shares to hold 7.7% as of June 30 — the largest single quarterly addition among the top 15 holders. Baker Bros., the specialist healthcare fund, already held 6.3% after building a 1.6 million-share position earlier in the year. Vanguard Capital Management reported an entirely new position of 1.39 million shares as of June 30. The institutional base is growing and skewing toward specialist life-science capital, which tends to be more patient through clinical volatility. Insider activity has been limited to a director's routine sales in late June; the 90-day net insider position is modestly positive at 11,600 shares, not a meaningful signal either way.
The ORTEX short score has drifted down from 65.7 a week ago to 64.4 today — a modest easing that tracks the stock's price recovery but still places PRAX in the upper tier of stocks under short pressure. The next scheduled earnings event is November 6, leaving the next three months dominated by clinical and regulatory news flow rather than financial results. The key watch item is whether FDA interactions around ulixacaltamide and relutrigine produce any newsworthy updates — any pipeline signal will likely move the short position more than price alone, with 9.2 days to cover acting as potential fuel in either direction.
See the live data behind this article on ORTEX.
Open PRAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
